ImmunoPrecise Antibodies Q1 2025 GAAP EPS $(0.15) Misses $(0.13) Estimate, Sales $5.300M Miss $6.750M Estimate
Portfolio Pulse from Benzinga Newsdesk
ImmunoPrecise Antibodies (NASDAQ:IPA) reported a Q1 2025 GAAP EPS of $(0.15), missing the $(0.13) estimate. Sales were $5.3M, below the $6.75M estimate, but up 24.35% from last year.
September 16, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ImmunoPrecise Antibodies reported a Q1 2025 EPS of $(0.15), missing estimates by 15.38%. Sales were $5.3M, missing estimates by 21.48%, but increased 24.35% YoY.
The company's earnings per share and sales both missed analyst estimates, which is typically viewed negatively by investors. Despite the year-over-year sales growth, the significant miss on both EPS and sales estimates is likely to lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100